This study confirms the durable efficacy and safety of guselkumab in Chinese patients with plaque psoriasis, with early response heterogeneity favoring the head. Treatment did not increase CAD or insulin resistance risk. Normal BMI and biologic-naïve status were associated with superior efficacy, supporting precision management strategies that integrate cutaneous and systemic monitoring.
Hu et al. (Tue,) studied this question.